Eribulin mesylate_product_DataBase

Bioactivity	Eribulin mesylate (E7389 mesylate) is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin mesylate inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.
Invitro	Eribulin (1-100 nM; 72 h) inhibits cells proliferation, with IC50s of 22.8 and 21.5 nM for LM8 and Dunn cells, respectively[1].Eribulin (10-50 nM; 12-72 h) increases early apoptosis significantly after 24 h treatment at the dose of 50 nM in LM8 cells[1].Eribulin (10-50 nM; 12-72 h) induces G2/M arrest by 12 h treatment with at the dose of 50 nM, but not by long-term treatment (72 h) with 10 nM in LM8 cells[1].Eribulin (1-50 nM; 12 h) does not induce senescence in LM8 cells[1].Eribulin (1-10 nM; 16 h) induces morphological change and suppresses cell migration in a low concentration in LM8 cells[1]. Cell Proliferation Assay[1] Cell Line:
Name	Eribulin mesylate
CAS	441045-17-6
Formula	C41H63NO14S
Molar Mass	826.00
Transport	Room temperature in continental US; may vary elsewhere.
Storage	-80°C, protect from light, stored under nitrogen

PeptideDB